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Parkinson’s disease (PD) is characterized as a chronic and progressive neurodegenerative
disorder that results in a variety of debilitating symptoms, including bradykinesia,
resting tremor, rigidity, and postural instability. Research spanning several decades has
emphasized basal ganglia dysfunction, predominantly resulting from dopaminergic (DA)
cell loss, as the primarily cause of the aforementioned parkinsonian features. But, why
those particular features manifest themselves remains an enigma. The goal of this paper
is to develop a theoretical framework that parkinsonian motor features are behavioral
consequence of a long-term adaptation to their inability (inflexibility or lack of capacity)
to meet energetic demands, due to neural metabolic deficits arising from mitochondrial
dysfunction associated with PD. Here, we discuss neurophysiological changes that are
generally associated with PD, such as selective degeneration of DA neurons in the
substantia nigra pars compacta (SNc), in conjunction with metabolic and mitochondrial
dysfunction. We then characterize the cardinal motor symptoms of PD, bradykinesia,
resting tremor, rigidity and gait disturbance, reviewing literature to demonstrate how these
motor patterns are actually energy efficient from a metabolic perspective. We will also
develop three testable hypotheses: (1) neural metabolic deficits precede the increased
rate of neurodegeneration and onset of behavioral symptoms in PD; (2) motor behavior
of persons with PD are more sensitive to changes in metabolic/bioenergetic state; and
(3) improvement of metabolic function could lead to better motor performance in persons
with PD. These hypotheses are designed to introduce a novel viewpoint that can elucidate
the connections between metabolic, neural and motor function in PD.
Keywords: Parkinson’s disease, motor deficits, neural metabolic deficits, mitochondrial dysfunction, behavioral
inflexibility
BACKGROUND AND INTRODUCTION
Parkinson’s disease (PD) is characterized as a chronic and progres-
sive neurodegenerative disorder that results in a variety of debil-
itating symptoms. The cardinal motor symptoms of PD include
bradykinesia, resting tremor, rigidity, and postural instability.
Research spanning several decades has emphasized dysfunctions
of basal ganglia, predominantly resulting from dopaminergic
(DA) cell loss, as the primarily cause of the aforementioned
parkinsonian features.
Classical pathophysiological model of PD, namely the “rate”
model (or two pathway model) (Albin et al., 1989; DeLong, 1990;
Wichmann and Delong, 1998; Wichmann et al., 2011), suggests
that abnormal activation or excessive inhibition of cortico-basal
ganglia-cortical loops resulting from changes in neuronal firing
patterns in the output channel of basal ganglia (i.e., substan-
tia nigra pars reticulata (SNr) and globus pallidus pars interna
(GPi)) is an essential feature of PD. The basal ganglia are a
group of interconnected subcortical nuclei, and they connect
with cerebral cortex, thalamus and other areas of the brain to
facilitate various motor functions (Albin et al., 1989). In the
classic rate model, there are two distinct pathways: direct and
indirect pathways, each of which appears to play a special-
ized role, and this is the concept central to this classic model
(Figure 1).
Briefly, while the direct pathway facilitates the desired motor
program for execution of the selected action by exciting the cor-
tex, the indirect pathway inhibits competing and unwanted motor
programs to efficiently execute the desired movement (Albin et al.,
1989; DeLong, 1990; Mink, 1996; Figure 1A).
Dopaminergic neuronal loss in the substantia nigra pars
compacta (SNc) affects both pathways differently, resulting in
decreased inhibitory inputs (via the direct pathway) and increased
excitatory inputs (via indirect pathway) to the GPi. As a whole
system, the rate model posits that dopamine depletion would
lead to an increase in tonic inhibition of thalamus and a reduc-
tion in excitatory drive to motor cortex (Fearnley and Lees,
1991; DeLong and Wichmann, 2007; Figure 1B). Therefore,
it is often thought that individuals with PD often manifest
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FIGURE 1 | Functional connectivity within the basal ganglia.
(A) Normal, (B) Parkinsonian state, and (C) paradoxical outcomes of
pallidotomy and pallidal DBS for PD. Black, white, and gray arrows represent
inhibitory, excitatory and dopaminergic (DA) transmissions, respectively.
Abbreviations: GPe, globus pallidus externus; GPi, globus pallidus internus;
SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata;
STN, subthalamic nucleus; DBS, deep brain stimulation.
subsequent reduction in movement (e.g., akinesia, hypokinesia,
and bradykinesia), as a consequence of the aforementioned dys-
function of basal ganglia (Albin et al., 1989; Vingerhoets et al.,
1997; Majsak et al., 1998; Lozza et al., 2002). Although this
classic model is widely accepted, it does not provide rational
explanations for some hyperkinetic features of PD, including but
not limited to dystonia, levodopa-induced dyskinesia, tremor, and
rigidity (Marsden and Obeso, 1994; Obeso et al., 2000, 2008;
Montgomery, 2007; Brown and Eusebio, 2008; Rodriguez-Oroz
et al., 2009).
The central tenet of the rate model is that increased GPi
discharge rate is at the core of PD, but a growing body of
literature has shown that GPi output rates in PD at rest are not
significantly different than the rate in controls in either MPTP
(Goldberg et al., 2002; Soares et al., 2004) or non-MPTP (Filion,
1979; Percheron et al., 1993) animal models. The model further
suggests that increased inhibition to thalamo-cortical projections
reduce neuronal activity in motor cortex, leading to a reduction in
motor behavior. However, many animal model studies refute this
postulation (Doudet et al., 1990). Furthermore, comorbidity of
hyper- and hypo-kinetic motor feature of PD cannot be explained
by the rate model because of its emphasis on explaining reduced
motor behavior. Perhaps, one of the major challenges to the
rate model is the effects of a pallidotomy (i.e., surgical lesion to
the GPi). According to the rate model, hyperkinetic movements
are the consequence of increased inhibition to the GPi by the
indirect pathway and resultant decreased inhibition of the thala-
mus, leading to the unwanted and excessive movements. Contrary
to the rate model, pallidotomy alleviates hyperkinetic features
such as tremor (Laitinen et al., 1992; Taha et al., 1997), dysto-
nia (Vitek and Bakay, 1997) and levodopa-induced dyskinesia
(Lozano et al., 1995; Lang et al., 1997; Figure 1C). Effectively,
these inconsistencies have driven researchers to explore alter-
native models, such as oscillator systems theory (Montgomery,
2007). In sum, the classic rate model is not sufficient to fully
and comprehensively explain PD. Therefore, it is imperative to
seek for an alternative model to answer the one simple, yet big
and unanswered, question; why do those particular parkinsonian
features manifest themselves? In other words, is the degenera-
tion of DA neurons directly related to particular parkinsonian
features? Or, are the motor symptoms of PD an indirect con-
sequence of long-term adaptation in response to these neuronal
losses?
While PD is generally viewed from the perspective of a neu-
rological disorder, there is now evidence that PD should also
be associated with metabolic dysfunction. Indeed, weight loss is
a well-known feature of PD (Kashihara, 2006), affecting more
than half of PD patients (Abbott et al., 1992). Intriguingly, this
weight loss in persons with PD appears to begin several years
prior to initial diagnosis, despite increased dietary intake (Davies
et al., 1994; Chen et al., 2003). Another possible sign of PD
prior to its onset is aggregation of alpha synuclein in the colon
(Shannon et al., 2012). One might not consider the buildup of
alpha synuclein in the colon as a direct metabolic problem, how-
ever, problems with feeding, bowel movements, and/or nutrient
absorption would indirectly contribute to energy deficits includ-
ing a shortage of metabolic substrate and reduced energy intake.
Furthermore, exaggerated susceptibility to fatigue even at lower
power outputs and elevated VO2 consumption during cycling
exercise regardless of power output demand is observed in PD
patients when compared to healthy elderly counterparts (Protas
et al., 1996; Stanley et al., 1999; Christiansen et al., 2009).
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The role of dopamine and energy metabolism in brain
function is intertwined. Schwartz et al. (1976) found that
dopamine lesions result in reduced glucose uptake in the fore-
brain, indicating that dysfunctional DA neurotransmission leads
to reduced substrate availability for neural metabolism. In addi-
tion, dopamine itself is related to glucose metabolism and insulin
sensitivity (Luo et al., 1997; Jetton et al., 2001), and thus,
the loss of dopamine neurons in PD is likely to contribute to
dysfunctional glucose metabolism. Interestingly, deficits in the
availability of metabolic substrate in the brain negatively affect
dopamine neurons. Chan et al. (1994) observed that a sudden
loss of adenosine triphosphate (ATP) levels in striatum led to
the loss of dopamine neurons. A growing body of literature
documents this vulnerability of DA neurons to energy deficits
(Brouillet et al., 1993, 1995; Zeevalk et al., 1995, 1997, 1998).
Collectively, these findings demonstrate that metabolic deficits
in the brain lead to the loss of dopamine function and vice
versa.
A growing body of literature argues that mitochondrial dys-
function is a common physiological feature in PD and is caus-
ing aggravated metabolic dysfunction (Chan and Mcquibban,
2013; Gaweda-Walerych and Zekanowski, 2013a,b; Lehmann and
Martins, 2013). Without question, metabolic energy is essential
to maintain the function of various organs and systems of the
human body. Chief among them, the brain requires a significant
proportion of total body energy expenditure, which is approxi-
mately 20–25% of total energy (Mink et al., 1981; Attwell and
Laughlin, 2001; Magistretti and Allaman, 2013). A reduction in
energy supply due to metabolic dysfunction, along with increased
brain energy costs due to neural communication deficits (see
Hong and Rebec (2012)), could be a central problem in PD that
has not yet received sufficient discussion. Metabolic deficits also
raise the possibility that the high metabolic demand in PD could
arise from DA neurons since DA neurons give rise to a large
number of synapses in the central nervous system (CNS).
The goal of this paper is to develop a theoretical framework
that parkinsonian motor features are behavioral consequence of
a long-term adaptation to their inability (inflexibility or lack of
capacity) to meet energetic demands, rather than being solely
a manifestation of dysfunction or deficiency of neural circuitry.
We will also develop hypotheses that can be tested based on the
overarching theory that PD motor symptoms are associated with
neural metabolic deficiencies.
BEHAVIORAL INFLEXIBILITY IN PARKINSON’s DISEASE
We often characterize PD as a set of distinct problems: slow-
ness, reduced movement, and tremor. Yet, when taken as a
whole, PD is truly a paradox where we observe both more
and less movement at the same time. When both the hyper-
and hypo-kinetic consequences of PD simultaneously, the dis-
order leads to a state where: (1) when the person wants to
move, he/she is stuck (bradykinesia, akinesia, and freezing); and
(2) when the person wants to stay still, he/she continues to
move (tremor). Essentially, the neuromotor system in PD suffers
from a problem of inflexibility, where the potential functional
range of behaviors that it can engaged in has been restricted.
Examples of inflexibility within the context of aging is a reduced
ability to generate both highly variable and highly repetitive
behaviors (see Vaillancourt and Newell (2002) for a review)
and an inability to control both high and low muscle force
outputs.
What then ensues is a question of the potential source of
inflexibility in PD. In our recent position paper on neural noise
and behavioral variability in aging, we proposed that a restriction
of metabolic capacity could be a central problem that restricts
flexibility in neural activation (Hong and Rebec, 2012). Effec-
tively, without sufficient metabolic fuel to both manage back-
ground noise and increase firing frequency, the brain is left with a
narrowed functional range. Perhaps, the same is true in PD, but at
a far more extreme level than observed in aging, where metabolic
problems are key components that shape PD symptoms. The
following sections review metabolic deficits in PD.
MITOCHONDRIAL DYSFUNCTION IN PARKINSON’s DISEASE
Mitochondrial dysfunction has been implicated as a cause of PD
(Abou-Sleiman et al., 2006; Banerjee et al., 2009). One of the
primary functions of mitochondria is to produce ATP through
the electron transport chain. The majority of energy consumed
in cellular activities is produced either directly or indirectly by
mitochondria. Thus, maintaining mitochondrial function is vital
for cell survival and thus strongly associated with both aging and
neurodegeneration like PD.
The association between aging and PD are once again gaining
attention and new investigations are being conducted. Further-
more, of a large number of risk factors of PD previously proposed,
one of the primary risk factors is aging. In fact, the average age of
onset is estimated at approximately 60–65 years (Twelves et al.,
2003). Approximately 1–2% of the population over age of 65 is
affected by this disease, and the proportion increases with age.
As a result, a growing body of literature proposes that aging and
PD could be related at the level of cellular mechanisms, where the
cell loss occurring with PD is more accelerated, exaggerated, and
region-specific (Collier et al., 2011; Bolam and Pissadaki, 2012;
Cai et al., 2012; Pissadaki and Bolam, 2013). Indeed, both aging
and PD share one progressive cellular change: mitochondrial
dysfunction.
A growing body of evidence suggests that mitochon-
dria interact with many proteins, including alpha-synuclein,
parkin, and PINK1, which are also associated with for-
mation of PD. Also, there appears to be an association
between mitochondrial function and parkinsonian features
since the neurotoxins used to generate animal models of
PD, 6-Hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP; Langston and Ballard, 1983;
Schober, 2004) affect mitochondria and replicate most of the
cardinal symptoms of PD (with the exception of Lewy body
formation). Overall, these lines of evidence present a view
of PD as a process of accelerated decline in the later stages
of life, above and beyond normal age-related deterioration of
function.
While the efficiency of energy production appears to be
reduced in aging due to the aforementioned mitochondrial
dysfunction, aging, in fact, also results in an increase in
energy expenditure for activities of daily living as well. For
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example, Martin et al. (1992) showed that the aerobic demands
for walking, which was normalized to body mass and walk-
ing speed, was 8% higher in elderly individuals than their
young counterparts. Higher energy expenditure during sub-
maximal movement tasks in elderly individuals has also been
consistently reported (Grimby and Soderholm, 1962; Waters
et al., 1983; Larish et al., 1988). Given that muscle mass and
strength decrease with advancing age, elderly individuals are
likely to face behavioral inefficiencies which require them to
recruit more motor units to produce sufficient force to meet
a given task demand (e.g., speed, steadiness, etc.) in compar-
ison with younger adults (Martin et al., 1992). Moreover, at
the neural level, energy costs would also be increased due to
a greater need for noise reduction and increased firing fre-
quency (Hong and Rebec, 2012). Thus, decreased muscular,
behavioral, and neural efficiency due to aging could lead to
compensatory adaptations in response to the increased energy
demands in order to maintain metabolic homeostasis (Schrack
et al., 2010). Effectively, PD is a situation where there are high
energetic demands that are accompanied by reduced energy sup-
ply (i.e., reduced substrate availability), prompting an energy-
conserving response.
NEUROPHYSIOLOGICAL ADAPTATION TO
ENERGETIC/METABOLIC DEFICITS IN PARKINSON’s DISEASE
Although the exact etiology of mitochondrial dysfunction in
PD still remains to be defined, it is a pivotal problem in PD.
Furthermore, the impact of such metabolic deficits on brain and
behavior are yet to be widely explored. However, the human
organ requiring the largest amount of energy is the brain, and
CNS deficits are central to the symptoms of PD. Specifically,
humans devote about 20–25 % of basal metabolism to the brain
(although it only weighs only 2% of total body weight), and most
of the energy consumed in the brain is to maintain electrical
activity in neurons (Mink et al., 1981; Magistretti and Allaman,
2013). While maintaining resting potential requires a relatively
small amount of energy (13% of total energy), almost half of
total energy (43%) is expended to fire action potentials (Attwell
and Laughlin, 2001). Moreover, energy costs of neuronal firing
increase as a function of firing frequency (Attwell and Laughlin,
2001).
Higher firing frequencies not only demand more metabolic
energy, they demand greater firing precision as well, essentially
due to a reduced “margin for error” in terms of neuronal informa-
tion transmission. Deviations or errors in neural activities are an
inherent phenomenon in the brain, as random background activ-
ity or neural noise is pervasive at all levels of the CNS (see Faisal
et al. (2008) for a review). Based on experimental and mathemat-
ical modeling, Tsubo et al. (2012) has demonstrated that neurons
attempt to maximize the amount of information (entropy) while
minimizing energy cost and noise on neuronal firing patterns,
namely conditional maximization firing-rate entropy hypothesis
(CMFE). In other words, neurons seek to find an optimal fre-
quency distribution of neuronal firing to maximize information
transmittal while suppressing energy cost and neural noise (Hong
and Rebec, 2012). Simply, noise reduction comes at a metabolic
cost.
Increased beta oscillation in PD could be another reflection
of a compensatory strategy for energy deficits. Oscillatory
activity can lead to more efficient temporal summation on
target neurons if it is constrained in a spatially discrimi-
nated scale, while it might also potentially reduce informa-
tion encoding capacity (indexed by entropy) if it occurs across
large populations of neurons (Uhlhaas et al., 2010; Little and
Brown, 2014). The increased beta activity could occur by
replacing high frequency firing patterns (energetically ineffi-
cient) with lower frequency oscillatory activities. Effectively,
the frequency distribution is likely compressed toward lower
frequency bands (e.g., pushing γ to β, β to α), improv-
ing the signal-to-noise ratio and reducing overall energy cost
at the expense of the amount of information that can be
transmitted.
Similar to the aforementioned neuronal adaptations observed
at the neurophysiological level of CNS, it is possible that there
are changes at the cellular (structural) level. Selective degenera-
tion of DA neurons within the SNc is considered to be one of
the major neurological complications associated with principal
parkinsonian features (Bolam and Pissadaki, 2012). Based on
this conceptual framework, the loss of DA neurons in the SNc
disrupts normal function of basal ganglia circuitry, resulting in
inadequate activation of desired motor programs and excessive
inhibition of undesired and competing programs (di Michele
et al., 2013). However, the causal relationship between DA neu-
rodegeneration and motor impairments in PD remains unclear. In
other words, is there a direct link between loss of DA neurons and
specific parkinsonian features? Is the neurophysiological change
observed in PD just a consequence of long-term behavioral
adaptations?
Research has begun to elucidate why DA neurons in the
SNc are exceptionally vulnerable and selectively and exception-
ally degenerated. A series of previous research has suggested
that the extreme energy cost is required to structurally and
functionally maintain the DA neurons in SNc because of the
large number of synapses of the these neurons when compared
to other regions and types of neurons. Specifically, the num-
ber of synapses from a single DA neuron of SNc in humans
was recently estimated by Bolam and Pissadaki (2012), based
on previous PD model studies in rats, which has shown that
there are about 12,000 DA neurons in the SNc (Oorschot,
1996; Nair-Roberts et al., 2008). It was estimated that a sin-
gle DA neuron of the SNc in rats gives rise to approximately
102,165 to 245,103 synapses at the level of striatum. In humans,
these synapses would be a few orders of magnitude higher as
compared to rats. In terms of other types of neurons in the
basal ganglia, the SNc gives rise to much higher numbers of
synapses by two orders of magnitude at the very least (Bolam
and Pissadaki, 2012). Furthermore, the unique length, exceeding
four meters, and complexity of their axons compound bioen-
ergetic deficits and contribute to their selective vulnerability
in PD (Pissadaki and Bolam, 2013). Based on these findings,
it was proposed that the high metabolic cost of DA neurons
makes them the first to face elimination in the face of an
energy shortage (Surmeier et al., 2010a,b; Bolam and Pissadaki,
2012).
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While more detailed research is necessary, it can be pos-
tulated that these neurophysiological changes occurring in the
basal ganglia, particularly SNc, can be considered as a neces-
sary adaptation, responding to lack of energy supply and/or
their susceptibility due to bioenergetic demand to maintain
their functional and structural characteristics. One should
also consider that persons with PD are likely to exhibit
neurobehavioral inflexibility since the constraint arising from
metabolic energy shortage will result in a narrowing of the
neural oscillation frequency range. More importantly, the ques-
tion that then arises is whether these alterations to neural
function could give rise to the motor behavioral symptoms
in PD.
BEHAVIORAL ADAPTATION AS AN “ENERGY SAVING”
STRATEGY IN PARKINSON’s DISEASE
Considering all of the literature reviewed in the paper thus
far, one would hypothesize that people with PD will have to
adapt their behaviors in order to overcome accelerated and exag-
gerated energy deficits. This adaptation could occur at various
levels: cellular, physiological and behavioral levels, as a means
of minimizing energy cost with respect to task, environmental
and other constraints (Sparrow and Newell, 1998). Daily energy
expenditure is indeed lower in PD patients compared to healthy
elderly, primarily due to reduced physical activity (Toth et al.,
1997). Conventional wisdom, would suggest that tremor would
lead to increased, rather than decreased metabolic cost (Poehlman
et al., 1995). Furthermore, alterations to gait in PD are gen-
erally considered to be less efficient than normal gait (Pelosin
et al., 2009). Both of these factors combined, would lead to
weight loss.
Indeed, symptom severity (i.e., increased tremor, rigidity, and
hypokinesia) is associated with greater weight loss in persons
with PD (Lorefält et al., 2004). Furthermore, a large body of
literature reports significant weight loss as an important prob-
lem in persons with PD (Abbott et al., 1992; Beyer et al.,
1995; Bachmann and Trenkwalder, 2006; Kashihara, 2006). It
is important to note that the weight loss occurs regardless of
increased energy intake (Davies et al., 1994; Chen et al., 2003;
Lorefält et al., 2004) or changes in daily energy expenditure
(Delikanaki-Skaribas et al., 2009), or with increased rest (Lorefält
et al., 2004). This raises a question as to whether symptom
severity is necessarily the cause of the weight loss, or, if it is
a response to other underlying metabolic issues that result in
weight loss.
Fluctuations in PD motor symptoms, even with levodopa
therapy, also raise another possibility that parkinsonian motor
features cannot be fully explained by dopamine depletion
alone. In a mouse model without metabolic deficits, Sotnikova
et al. (2005) demonstrated that PD behavioral phenotype of
transient depletion of striatal dopamine can be reversed suc-
cessfully using levodopa. Yet, PD patients initially respond
well to the introduction of levodopa, but face a progres-
sive decline in the benefits of levodopa administration after
a few years (Chase, 1998). Assuming dopamine loss is the
primary source of parkinsonian motor features, levodopa therapy
should be sufficient to restore and stabilize motor function. In
other words, symptom severity and its fluctuations throughout
the day should be strongly associated with dopamine lev-
els and predictable based on dose and half-life of levodopa,
i.e., how much of the drug is given, and how quickly its
effects wear off. However, long-term administration of DA
therapy, which is supposed to solve dopamine shortage and
optimally regulate the dopamine level, cannot fully control
motor symptoms, or even worsen them (e.g., motor fluctuation,
levodopa-induced dyskinesia and sleep disturbance) (Fahn et al.,
2004).
Alterations to metabolic function provide a potential expla-
nation for the variability and continued fluctuations in motor
symptoms despite therapy. A good example of such phenom-
ena is a change blood glucose fluctuation patterns that become
dysfunctional in people with metabolic syndrome and type II
diabetes (Churruca et al., 2008; Costa et al., 2014). While healthy,
normoglycemic individuals exhibit rapid, small, and irregular
blood glucose fluctuations throughout the day, people with
metabolic syndrome and type II diabetes exhibit slow, large,
and systematic changes in blood glucose levels. This “loss of
complexity” has been observed in aging (Lipsitz and Goldberger,
1992; Goldberger et al., 2002) and a variety of other disorders,
including PD (Vaillancourt and Newell, 2002). This is con-
sistent PD symptom fluctuations where there are large, slow,
and systematic fluctuations, where “on” periods are very good,
while “off ” periods lead to severe symptoms. In addition, a
body of previous studies suggested that DA levels and motor
symptom severity are not strongly correlated (Mouradian et al.,
1987, 1988; Fabbrini et al., 1988; Chase, 1998). Given that PD
symptoms generally do not appear until a large proportion of
DA neurons (∼80%) in SNr are degenerated (Marsden, 1990;
Lang and Lozano, 1998; Dauer and Przedborski, 2003; Ross
et al., 2004), a critical question arises; how can motor fluctu-
ations still occur when a majority of the DA neurons in SNr
have been lost? In other words, the limited number of neurons
will also limit the potential variation and range of DA levels
that can be produced, thus leading to relatively stable symp-
toms. Metabolic fluctuations provide a potential explanation
as to why symptom fluctuations exist, and further declines in
metabolic function explain the gradual resistance to levodopa
therapy.
Here, we propose that the cardinal movement disorders of PD
could be the consequence of an adaptive compensatory response
to the decreased ability to meet metabolic demands for activities
of daily living (Figure 2). For instance, Schrack et al. (2010)
suggested that elderly individuals are likely to develop their adap-
tive behaviors (e.g., reduced walking speed) to conserve their
energy since essential energy (i.e., the energy essential for living)
is increased with age, resulting in decreased available energy (i.e.,
the energy available to an individual in addition to the resting
metabolic rate (RMR)). Therefore, parkinsonian motor features
could possibly be considered as economizing, which is similar
to adaptive behaviors observed in elderly individuals (Schrack
et al., 2012). Thus, the question that arises is whether it is
possible that the motor symptoms of PD could in fact be energy-
saving strategies. We will explore this possibility in the subsequent
sections.
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FIGURE 2 | Schematic illustrating the adaptive strategy in response
to energy imbalance in persons with PD. Persons with PD exhibits
reduced energy supply (limited available energy), whereas resting
metabolic rate (RMR) and activity energy expenditure (AEE) are
increased. As a result, energy depletion would occur without any
compensatory adaptations. We propose that parkinsonian motor
features are behavioral consequences of long-term adaptation to a
neural metabolic deficit in persons with PD.
Bradykinesia, which describes slowness of voluntary move-
ments, is usually one of the most disabling symptoms for per-
sons with PD. Bradykinesia presents in the early stages of the
disease, often accompanied by hypophonia (slow speech; Liotti
et al., 2003), micrographia (small writing; McLennan et al., 1972;
Oliveira et al., 1997), and saccadic hypometria (small eye move-
ments; Choi et al., 2011). Similarly, gait in persons with PD can
be characterized as bradykinetic gait with reduced speed and step
length (Morris et al., 1996). Although decreased cortical activity
as a consequence of altered basothalamic outputs (exaggerated
inhibitory outputs toward cortical areas) appears to be associated
with bradykinesia, the exact underlying mechanism is unclear
(Hallett, 2003; Wichmann and DeLong, 2003). Here, a decrease in
cortical activity would also be consistent with energy conservation
at the neural level, reducing the number of action potentials
needed.
Behaviorally, micrographia can be improved when visual cues
to write larger (lined paper) are provided to persons with PD,
i.e., when cued them to write larger (McLennan et al., 1972).
This phenomenon is consistent with another previous finding
that persons in PD are capable of walking just as fast as their
age-matched counterparts, but are less able to maintain the target
speed for prolonged periods of time (see Lim et al. (2005) for
a review). Essentially, the physical capacity (for lack of a better
phrase) to achieve motor task demands remains in place. These
studies indicate that persons with PD seem to function at a
lower proportion of their maximal capacity. This suggests that
the reduced movement speed observed in individuals with PD do
not necessarily arise from an inability to perform the movements
per se.
This leaves the question of what potential internal mechanisms
might be prohibitive of the performance of fast movements.
From a muscle activation standpoint, bradykinesia has the benefit
of demanding the recruitment of slower motor units, reduc-
ing the demand for activation of the more energy expensive
type II or fast-twitch fibers (Bottinelli et al., 1994; Zierath and
Hawley, 2004; Schiaffino and Reggiani, 2011). For the pur-
pose of voluntary movements, an endpoint always exists at
the termination of an actions and/or the preparation of sub-
sequent action plans. For instance, when people reach to an
object to grasp, there are a series of motor tasks to com-
plete: initiation of reaching movement, acceleration-deceleration
of the arm, preparation of grasping (creating hand aperture
prior to a grasping action). The ultimate goal of this reaching
task is to minimize deviations from the optimal final position
needed to grasp an object efficiently, not necessarily to minimize
the duration to reach the object, under the assumption that
neural noise is signal-dependent (Harris and Wolpert, 1998).
As a result, moving faster is energetically more expensive as
large control signals consume more energy for action potentials
(Attwell and Laughlin, 2001) and noise reduction (Tsubo et al.,
2012).
There is an additional energetic benefit for moving slowly in
order to minimize undesired movement variability that interferes
with task performance. The neuromotor system is thought to
attempt to keep adjustments to task-related motor variance to
a minimum, hence the term “minimum intervention principle”
(Todorov and Jordan, 2002; Todorov, 2004). Effectively, task-
irrelevant behavioral variability is generally disregarded as long
as it does not affect the task goal. This also means, however,
that faster movements will result in larger errors that in turn
will require larger corrective movements, i.e., larger muscle con-
tractions. Thus, these converging concepts raise the possibility
that motor slowing is a compensatory adaptation to minimize
task-relevant variability, and this adaptation is manifests itself as
bradykinesia in PD.
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GAIT DISTURBANCE
Much like the problem of bradykinesia, Parkinsonian gait is
also hypokinetic, which can be characterized by spatiotemporal
disturbance compared to neurologically healthy individuals. Even
in normal aging, seniors tend to walk more slowly to compensate
for the increased energy cost of walking (Schrack et al., 2012).
Persons with PD often walk slower with greatly reduced step
length, accompanied by slowed and decreased arm swing (for a
review, see Amano et al., 2013). Although neurodegeneration is
believed to be related to the impairment in functional motor tasks,
energy cost of gait performance could also critically contribute
to its decline since preferred level of energy cost is likely to
be associated with speed of movement (Taylor, 1985; Waters
et al., 1988). Indeed, previous research showed that the preferred
gait frequency is self-optimized and could be predicted by the
resonance properties of the limb so that work executed by muscles
and the energetic requirements to maintain gait can be minimized
(Holt et al., 1991). Simply, walking slower or faster than the
natural speed “prescribed” by one’s body proportions leads to a
higher metabolic cost.
Gait is a complex motor task that includes both active and
passive control mechanisms, according to previously-reported
mathematical modeling (McGeer, 1990; Bauby and Kuo, 2000;
Kuo, 2007). While forward propulsion can be maintained with
little actuation and no active adjustments, lateral (side-to-side)
stability cannot be achieved without active sensorimotor control
(Bauby and Kuo, 2000; Donelan et al., 2001). This active lateral
balance control in the mathematical walking model can be com-
patible with PD gait since they have more difficulty in maintaining
lateral stability rather than forward propulsion (Van Wegen et al.,
2001; Horak et al., 2005; King and Horak, 2008).
Reduced step length and an increase in double-limb support
time, both characteristic of PD gait, are beneficial for stabil-
ity, leading to altered biomechanical gait pattern. Superficially,
this compensatory gait strategy would seem to require more
energy, and indeed, previous studies suggest that this abnor-
mal gait pattern leads to poorer economy of gait (i.e., higher
sub-maximal VO2 /VO2max) in persons with PD when com-
pared to age-matched healthy individuals (Christiansen et al.,
2009; Katzel et al., 2012). It is especially important to note
here that Katzel et al. (2012) calculated gait economy based
on measured VO2 as a proportion of predicted VO2 using the
American College of Sports Medicine (ACSM) equation. The
ACSM equation, however, only takes walking speed into account
and does not include height or body mass in the calculations.
What this does is make an assumption that persons with PD
walk at any given speed with similar biomechanics to healthy
controls. Moreover, at the same absolute speed, the person with
PD would be walking at a higher relative speed (i.e., higher
percentage of maximum) than an age-matched control. As a
result, it is not yet certain whether or not the aforementioned
biomechanical changes in gait pattern of persons with PD pri-
marily result in elevated energy requirements during walking.
These altered spatiotemporal gait parameters are simply end
products of a multifactorial motor task comprising precise neural
motor commands, efficient force productions and joint motion
control, and adequate postural stability against any postural
threats, all of which could burden the energy requirement
of gait.
If considered more deeply, the PD gait pattern is actually a
means of making a slow and low amplitude gait pattern more
energy efficient. The stooped posture often observed in persons
with PD is a critical factor. This stooped or hunched posture
enables persons with PD to lower their center of mass (COM).
This is based on the premise that minimizing the displacement
of COM as much as possible is the best way to achieve eco-
nomical gait. Moreover, the shift in whole body COM alters
the individual’s preferred (biomechanically optimal) gait pattern.
By reducing the height of COM and step length, persons with
PD can alter the length of pendulum (lower extremity in gait),
resulting in change of its resonant frequency. Given that the
resonant frequency is a primary determinant of walking speed
(Holt et al., 1991), gait efficiency in persons with PD could
be either maintained or improved through these biomechanical
(symptomatic) modifications.
In short, a parkinsonian gait pattern on an absolute scale
is energetically inefficient, when compared against the biome-
chanics of age-matched normal gait. But given the motor con-
trol constraints, parkinsonian gait is an energy efficient strategy
that would likely lead to lower energy expenditure, if com-
pared to age-matched controls forced to walk with a reduced
step length and gait speed. The ability of a neuromotor system
that has been affected by PD to make active adaptations to
modulate gait patterns and accommodate unwanted variability
arising from the passive gait dynamics is diminished. Slow-
ing the gait pattern in conjunction by altering the mechani-
cal resonance of the body would at the minimum prevent a
net change in energy efficiency if it does not reduce metabolic
cost.
TREMOR AND RIGIDITY
Perhaps the least intuitive, but potentially cost-saving compen-
satory adaptation is tremor. On the surface, one would immedi-
ately posit that tremor would require increased muscle activity,
and consequently, a higher level of energy expenditure. Some
would argue that tremor appears to be almost paradoxical to
the hypokinetic/bradykinetic features of PD, as it is an increase
in movement amplitude. Intriguingly, the severity of tremor
is not necessarily related to disease progression, unlike rigid-
ity and akinesia (Deuschl et al., 2000). Certainly, the patho-
physiology of PD tremor is suggested to be different from
that of the other parkinsonian features (Zetusky et al., 1985;
Fishman, 2008; Zaidel et al., 2009; Mure et al., 2011). Further,
parkinsonian tremor appears to be associated with abnormal
neuronal synchronization in the cortico-baso-thalamic circuitry
(Deuschl et al., 2000). Therefore, thalamus and subthalamic
nucleus are considered as the primary targets for deep brain
stimulation to suppress PD tremor. However, the direct causal
relationship between parkinsonian tremor and the aforemen-
tioned central oscillators remains an enigma (Lemstra et al.,
1999).
However, we believe that tremor can also be explained as a
long-term compensatory behavioral adaptation to energy imbal-
ance. Tremor is defined as hyperkinetic, involuntary and rhythmic
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oscillations of body segments (Deuschl et al., 2001), and it is one
of the cardinal, as well as classical, motor features in PD (Zetusky
and Jankovic, 1985; Zetusky et al., 1985; Farlow et al., 1993).
Tremor, however, is not simply a feature of PD, but is present at
rest and during postural control of the limbs in all individuals,
although, most often normal tremor is generally invisible to the
naked eye (Elble and Koller, 1990). In healthy individuals, the
dynamics of resting tremor represent a combination of a variety
of different intentional, neuromuscular, and mechanical sources,
often ranging from 7 to 13 Hz (Allum et al., 1978). Parkinsonian
tremor can be described as a resting tremor with a frequency
typically occurring between 4–7 Hz, although tremor at higher
frequencies has also been reported, especially in the early stages
of the disease (Koller and Huber, 1989; Paulson and Stern, 1997;
Deuschl et al., 2000). The most important factors that distinguish
between parkinsonian tremor and normal resting tremor are as
follows: (1) high frequency oscillations are absent in PD tremor
(Vaillancourt and Newell, 2000); and (2) the power spectral
density of PD tremor is narrow and concentrated around the
4–7 Hz frequency range, while power is more evenly distributed
across the frequency range in normal resting tremor. By removing
high frequency components of healthy tremor, there are two
sources of energy cost savings that can be associated with PD.
First, neuronal firing would be reduced, lowering the metabolic
cost within brain structures associated with neural sources of
tremor. Second, recruitment of faster and larger motor units
would be reduced or possibly even eliminated. This would lead
to a reduction in energy demands from fast-twitch fibers in the
musculature.
The second energetic cost savings of PD tremor lies in its
restriction to the mechanical resonance of the hand and arm.
It is important to reiterate the energetic benefits of shifting
tremor toward mechanical resonance. Movements performed
at mechanical resonance exploit the inherent elastic proper-
ties of the muscle and limb dynamics to increase the “bounce
for the ounce,” insofar that the need for active muscle con-
tractions to perform the movement is reduced (Kugler et al.,
1980; Kugler and Turvey, 1987; Holt et al., 1991). The abil-
ity to move at determined resonance movement frequencies
(even when interacting with the environment) develops at a
very early age (∼8 months old), suggesting that this is an
inherent component of human motor control (Goldfield et al.,
1993). Moreover, even normal physiological tremor has been
argued to be driven almost exclusively by mechanical fac-
tors, and a mathematical model demonstrates that physiolog-
ical tremor can be generated in the absence of neurological
input (Lakie et al., 2012). In addition, movements performed
at resonance are also more stable and repeatable (Goodman
et al., 2000). This line of evidence would indicate that parkin-
sonian tremor further reduces cost by exploiting the spring-
like properties of the musculature to minimize the need for
active contraction. Effectively, PD tremor conserves the kinetic
energy by “utilizing the natural springiness” of the muscles
to reduce the need for active muscle contractions to maintain
posture.
One also has to keep in mind that at least some components
of the tremor pattern are driven by oscillations in the CNS. If
the frequency range over which the PD brain is able to transmit
is limited by metabolic deficits, a possible reason why the high
frequency components of healthy resting tremor is absent in
PD. It is also possible that DBS therapy is particularly beneficial
for the treatment of tremor, by externally reintroducing high
frequency neural oscillations, minus the internal energy costs.
Unfortunately, it cannot resolve problems at lower frequencies,
a possible explanation as to why slower behaviors, such as gait
are generally not affected positively by DBS therapy (St George
et al., 2010). This would suggest that the lifting of the metabol-
ically defined constraint on maximal firing frequency in the PD
brain is required in order for all PD motor symptoms to be
ameliorated.
Rigidity is another PD feature that, on the surface, does not
appear to be an energy cost-saving compensatory adaptation.
Rigidity is characterized as an increased resistance during a pas-
sive stretch of a muscle (Delwaide, 2001). Seemingly, rigidity
appears to be an energy-wasting phenomenon since it results from
uncontrolled and sustained muscle co-contraction, continuously
consuming energy where muscles spend more time being “on”
than “off.”
Also at the neuronal level, Takakusaki (2013) documented
that increased GABAergic signal from the output channel of
the basal ganglia, which is the feature of PD, could result in
excessive inhibition of the brainstem muscle-tone inhibitory sys-
tem, leading to muscle tone rigidity. There is little doubt that
in a normally functioning neural system, excessive synchrony
is clearly detrimental and wastes energy as it prevents the sys-
tem from transitioning smoothly from postures to movements
(Hutchison et al., 2004; Walters and Bergstrom, 2009; Avila
et al., 2010), effectively “trapping” the system in place. Indeed,
a healthy nervous system is able to move between the extremes
of coordinated firing patterns, and high levels of synchrony are
unnecessary and in fact counterproductive. Yet, in the case of
PD, we are faced with neural and metabolic systems that are
now inflexible (i.e., restricted to a limited number of coordi-
nated neural firing states and metabolic energy sources). Thus,
when one considers the narrow functional range with PD (i.e.,
reduced capacity for noise reduction and maximal firing rate), a
statistical advantage of remaining in the middle becomes more
economical as large-scale transitions in coordinated firing, noise
levels, or firing rates are needed. Simply, because the system can
no longer achieve extreme states, regressing toward the media
allows the system to achieve a state of “compromise” at the neuro-
metabolic level, albeit from a motor function perspective, it leads
to impairments.
As a result, when one considers the problem more deeply from
the standpoint of muscle activation dynamics, a vastly differ-
ent picture emerges. Much like holding a still posture, allowing
smooth and passive motion of a limb requires two major com-
ponents: (1) out-of-phase firing off the agonist and antagonist
musculature, preventing co-contraction; and (2) high frequency
firing patterns to prevent jerking of the limb. Rigidity is energy
efficient in such a way that it reduces the firing frequency of
the motor units. Another important component of rigidity is
the in-phase co-contraction of agonist and antagonist muscles.
Anti-phase activation demands that muscle force be signaled and
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generated by each muscle independently. By firing the muscula-
ture in a synchronous, in-phase pattern, energy cost savings can
be realized as a single signal can now be sent to both muscles and
both signals now have a facilitative effect, essentially, doubling
the force output with a single signal. Indeed, rigidity is by no
means functional, but is a clear reflection of the inflexibility in
the PD motor system, where behaviors are limited to a narrow
functional range within a framework of energy cost savings
(Figure 3).
SUMMARY
Unfortunately, saving energy during brain activation and motor
function comes at the cost of flexibility. This form of inflexibility
in PD is particularly evident in a reduced ability to transition from
posture to movement (and vice versa), resulting in difficulties in
movement initiation and termination. What makes movement
initiation difficult is the fact that voluntary movements are ini-
tiated in coincidence with the direction of the tremor (Cohen
and Rosenbaum, 2007). An analogy for such a process is that
movement initiation is akin to jumping onto a swinging pendu-
lum. Normal resting tremor, due its high frequency oscillations,
changes directions at a very fast rate. In addition, the lower
amplitude of normal tremor reduces the need for large levels of
muscle activation to overcome tremor to begin a goal-directed
action. Parkinsonian tremor on the other hand, is a relatively
slow and high amplitude oscillation. First, the neuromotor system
has a longer waiting period in order to “catch the next wave”
so that the movement can be initiated in conjunction with the
direction of the tremor. The slowness of PD tremor would result
in directional changes occurring with a far lower frequency. In
addition, because PD tremor exploits the spring-like nature of the
musculature, persons with PD have to generate a larger muscle
force to overcome the “bouncing” generated by the tremor in
order to start movement.
In summary, in persons with PD, it can be speculated that,
to minimize energy cost, active control (e.g., lateral stabiliza-
tion during gait, smooth motions of a limb, and suppression
of tremor) appears to be compromised and diminished since
it requires energy, and passive control (e.g., movements on the
plane of progression during gait) is more inflexible since altering
an automated behavior also requires energy. Hence, although
mechanisms of PD tremor and parkinsonian gait do not seem
to be identical (since tremor is hyperkinetic and gait is pre-
dominantly hypokinetic feature), both of them could possibly
emerge from a single origin: metabolic dysfunction or energy
imbalance. This speculation could be extended to difficulty in gait
initiation (GI) and termination (GT) in persons with PD since
both GI and GT require active control to initiate or terminate
forward propulsion. Metabolic cost is required to voluntarily
transition from one passively-stable condition to another. Taken
together, all of these previous findings could indicate that persons
with PD lack behavioral flexibility which should be necessary
to adapt to environmental changes (e.g., a sudden perturba-
tion) and/or task demands (i.e., GI and GT) since energy is
required for these adaptations. It can also be postulated that
this inflexibility emerged as a compensatory action for persons
with PD since self-optimization of biological systems and age-
related adjustment are insufficient to off-set the energy imbalance
in PD.
HYPOTHESES AND FUTURE DIRECTIONS
While we outlined a new perspective on metabolic dysfunction
and parkinsonian motor features in this theory-and-hypothesis
paper, there are still a number of unanswered questions that are
critical to understand the underlying mechanisms of features of
PD and the relationship to their neural metabolic deficits. It is a
particularly important avenue to explore to develop an empirical,
comprehensive, and effective therapeutic strategy for this patient
population.
To date, while the effectiveness of currently-available treat-
ments, such as levodopa and DBS, is clinically accepted, and
thus widely applied to a number of patients throughout decades
(Deep Brain Stimulation for Parkinson’s Disease Study Group,
2001), their mechanism of their action, particularly DBS, does
FIGURE 3 | Schematic illustrating the difference between
in-phase and anti-phase firing pattern. (A) Firing the
musculature (e.g., agonist and antagonist muscles) in an in-phase
pattern can facilitate an additive effect, which doubles the force
amplitude with a single signal in comparison to (B) anti-phase
firing patterns. Note the difference in the resultant amplitude
between in-phase and anti-phase activation. Abbreviations: A,
amplitude; λ, wave length.
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not appear to be fully empirically supported (Montgomery and
Gale, 2008). Furthermore, while a large number of clinical studies
consistently report DBS to be effective in alleviating bradykinesia,
tremor, and rigidity (Deep Brain Stimulation for Parkinson’s
Disease Study Group, 2001; Rodriguez-Oroz et al., 2005), it does
not appear to improve postural instability and gait disturbance,
and in some cases DBS worsens these symptoms over the long
term (Follett et al., 2010; St George et al., 2010). The inconsistent
effects of DBS in cardinal parkinsonian motor features indicate
that there is more to PD than the rate model explains. These
results suggest that despite the “added” DBS frequency to the
underlying neural activity cannot reverse what the metabolic
constraints have placed on the CNS, most likely in the realm
of noise reduction (a process that requires metabolic energy).
Failure to provide an effective treatment to globally improve
parkinsonian motor symptoms is, at least partially, due to lack
of understanding of the underlying mechanism causing PD and
limitation of the current accepted model of PD (i.e., the rate
model).
Here, we develop three hypotheses to test our new theoretical
framework: (1) neural metabolic deficits precede the increase
rate of neurodegeneration and onset of behavioral symptoms in
PD; (2) motor behavior of persons with PD are more sensitive
to changes in metabolic/bioenergetic state, where persons with
PD will optimize their motor behavior to minimize energy; and
(3) improvement of metabolic function could lead to better motor
performance in persons with PD.
HYPOTHESIS 1—NEURAL METABOLIC DEFICITS PRECEDE THE
INCREASED RATE OF NEURODEGENERATION AND ONSET OF
BEHAVIORAL SYMPTOMS IN PD
One of the major gaps in literature in PD is that the primary
cause of this disorder remains unknown. Throughout this paper,
we discussed neural metabolic deficits in PD, as potential key
factors in its development and behavioral symptoms by way of
minimizing energy for survival. Development of PD is usually
a long-term process where somehow, the natural loss of DA
neurons with age is accelerated, a deviation from the normal
trajectory of human aging (Collier et al., 2011). Previous studies
have already shown that the onset of PD precedes the motor man-
ifestations; the pre-symptomatic phase of PD last approximately
20 years or even more (Savica et al., 2010). In fact, PD is usually
diagnosed when a certain symptoms become apparent. This lag
between the time when diagnosed and the actual disease onset can
be also observed in a neurophysiological system: approximately
a half of nigrostriatal DA neurons are lost by symptom onset
(Fearnley and Lees, 1991). The fact that gradual, yet continuous,
processes are central to the development of PD symptoms appears
to support our hypothesis that neural metabolic deficits might
well precede the increased rate of neurodegeneration and onset of
behavioral symptoms in PD. To test this hypothesis, an important
next step would be a prospective longitudinal (cohort) study
in genetic models of PD, such as parkin knock-out mice, to
determine whether metabolic dysfunction (diminished metabolic
flexibility) is central to the neurodegeneration in PD. Parkin is
an E3 ubiquitin-protein ligase (Shimura et al., 2000), which plays
a pivotal role in mitochondrial function in such a way that it
is selectively recruited to promote the autophagy of impaired
mitochondria (Narendra et al., 2008). As a result, a mutation
in Parkin results in increased mitochondrial aggregation and
reduced autophagy of damaged or non-functional mitochon-
dria. Taken together, loss of parkin function could eventually
lead to loss of mitochondrial integrity/function in DA neurons
(Palacino et al., 2004; Casarejos et al., 2006; Yu et al., 2011).
Hence, parkin knock-out mice are adequate to test this hypoth-
esis since a recent study suggest knocking out parkin in mice
at adult age causes neurodegeneration in the SNc (Shin et al.,
2011), while knock-out animal models of other genes, such as
PINK1 (phosphatase and tensin homolog-PTEN-induced novel
kinase (1), α-synuclein, LRRK2, and DJ-1 do not demonstrate any
nigrostriatal degeneration (Moore and Dawson, 2008; Blesa et al.,
2012).
It is important to note, however, that not all parkin models
result in DA neuron loss in SNc. While some parkin mod-
els (e.g., Q411) lead to dopamine neuron loss and behav-
ioral changes (abnormal locomotor activation, hypoactivity,
and impaired balance Lu et al., 2009), the other model (e.g.,
B6.129S4-PARK2tm1SHN /J) results in mitochondrial dysfunction
and behavioral impairments in the absence of nigral degeneration
(Goldberg et al., 2003). This conflicting result in animal model
studies of PD arise from an important limitation: the progressive
nature of the disorder. Without this key feature in all PD models,
we cannot perfectly replicate the disease in human conditions
and understand metabolic deficits, DA neuron loss, and motor
symptoms are interconnected and which ones precede others in
actual humans. In short, none of the existing animal models of
experimental PD completely mimics the etiology, progression,
and pathology of human PD (Martinez and Greenamyre, 2012).
As mentioned earlier, Sotnikova et al. (2005) were able to reverse
parkinsonian motor features resulting from acute dopamine
depletion (e.g., akinesia, rigidity, tremor). The acute lesion or
dopamine deficiency is not progressive, and in fact, many animal
models, including primates, can recover from unilateral MPTP
lesions (Boulet et al., 2008; Meredith and Rademacher, 2011).
Moreover, PD manifests many features at various levels (cellular,
structural, and functional), the aforementioned “acute” models
can only partially replicate the disease (See Figure 4). Collectively,
these empirical findings would suggest that the loss of DA neurons
in striatum and the SNc, specifically, is not the “trigger point” of
the disorder that ignites the cascade of symptoms and progressive
neurodegeneration.
Comparison of the metabolic functions of both of these
models should provide a clear means of testing Hypothesis 1.
First, both models should demonstrate a degree of impaired
metabolic function. Given that predominant use of carbohydrate
(i.e., higher respiratory quotient) in aging appears to result in
longevity (Rizzo et al., 2005), we should expect to see lower RQ
values in both of the aforementioned parkin mouse models in
comparison to age-matched controls, a process that precedes the
onset of symptoms and neuron loss. This can be achieved by
testing the mice in a metabolic cage. Second, a further metabolic
challenge to the B6.129S4-PARK2tm1SHN /J should lead to the loss
of DA neurons. Third, the loss of DA neurons in the Q411 mice
should be accelerated by a further metabolic challenge.
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FIGURE 4 | Framework illustrating the causal relationship between
neural metabolic deficits, various levels of adaptations, and
consequential parkinsonian motor features. Due to metabolic dysfunction,
persons with PD continuously require neurophysiological (i.e., selective
dopaminergic cell loss) and behavioral (i.e., implementation of
“energy-saving” strategy) adaptations to compensate for their energy
imbalance. In our proposed framework, parkinsonian features manifest as a
series of long-term adaptive consequences. Black arrows illustrate how
alternation in each animal PD model results in Parkinsonian motor symptoms.
It is important to note that currently-available animal models cannot fully
replicate PD in humans (e.g., mitochondrial dysfunction in
B6.129S4-PARK2tm1SHN /J, and dopaminergic cell loss in Q411).
The strongest empirical outcomes would arise from experi-
ments where the symptoms of PD can be induced in normal
control mice through manipulations of metabolic function over
a prolonged period of time without the need for lesions to
the SNc. For example, Bassil et al. (2014) have proposed that
GLP-1 (glucagon-like peptide-1) is deficient in PD and other
neurodegenerative disorders, while IGF-1 (insulin-like growth
factor-1) levels are excessive. A good test of Hypothesis 1 would
be an experiment where IGF-1 levels are increased and GLP-1
actions are blocked at different points in the animal lifespan. If
the hypothesis is correct, these animals will exhibit PD symptoms
later in life.
In Sum, if this hypothesis holds true, our theoretical frame-
work would suggest investigating underlying mechanisms causing
the metabolic dysfunction and energy imbalance is vital to further
understand the primary cause of PD, rather than subsequent DA
cell loss. Ultimately, this approach could help developing a new
diagnostic tool for: (A) early detection of PD; and/or (B) better
PD risk-factor determination.
HYPOTHESIS 2—MOTOR BEHAVIOR OF PERSONS WITH PD ARE MORE
SENSITIVE TO CHANGES IN METABOLIC/BIOENERGETIC STATE
Knowing that PD motor symptoms are adaptations to underlying
metabolic dysfunction, then there is the possibility that the motor
symptoms can be exacerbated by changes in metabolic state
and that inability to implement proper behavioral adjustments
corresponding to these changes could result in aggravated fati-
gability. In fact, fatigue is one of the major and most common
non-motor problems in persons with PD, approximately 44%
of PD patients reported subjective fatigue (Karlsen et al., 1999).
In addition, individuals with PD are also more easily fatigued
during motor tasks (i.e., decay of maximum force production
relative to individuals’ peak force throughout muscle activation)
than healthy counterparts during sustained maximum isometric
forearm flexion task (Ziv et al., 1998). These findings demonstrate
the potential link between metabolic state and motor function.
Building on the aforementioned studies, further evidence of the
link between metabolism and motor function in PD could be
improved by additional physiological measurements. For exam-
ple, blood lactate assays could be obtained, or measures of
oxygen consumption and respiratory quotient could be intro-
duced. These physiological measurements would yield further
insight into the metabolic state of the individual during the
fatiguing task, that could be in turn be correlated with motor
patterns.
Other tests that provide perturbations to metabolic state
could also be employed. As another example, the test of
metabolic flexibility, i.e., a hyper-insulinemic clamp could be
used to alter RQ in human subjects. Subjects could then
undergo motor testing, e.g., gait, tremor, etc. One would
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thus predict that the hypo- and hyper-kinetic features of
PD will be affected by the change in metabolic state, but
not in healthy controls. There are other potential manipula-
tions to metabolic state through dietary factors and nutritional
supplements.
HYPOTHESIS 3—IMPROVEMENT OF METABOLIC FUNCTION COULD
LEAD TO BETTER MOTOR PERFORMANCE IN PERSONS WITH PD
If the aforementioned two hypotheses hold true, we need to
consider changing the course of designing effective therapeutic
options for this population: from finding optimal symptom-
specific interventions (e.g., walking faster, regaining balance and
reducing tremor amplitude) to new approaches focusing on
metabolic/bioenergetic restoration and improving metabolic flex-
ibility. These approaches are based on cumulative evidence from
both animal and postmortem human brain tissue, implicating
mitochondrial dysfunction in PD (Beal, 2005; Lin and Beal,
2006; Chaturvedi and Beal, 2008, 2013). Moreover, Morais et al.
(2014) recently investigated the link between energy deficits and
PD using mice and fruitflies with a defective PINK1 gene and
demonstrated that the defect resulted in a specific loss of phos-
phorylation in Complex I, which is associated with decreased
energy production. Intriguingly, however, they also showed that
Complex I deficits and energy production could be rescued in
cells derived from patients with PINK1 mutations after restoring
correct phosphorylation of Complex I, and that parkinsonian
symptoms consequently decreased or disappeared. Effectively,
these aforementioned studies raise the possibility that rescu-
ing a genetic component of mitochondrial dysfunction and/or
restoring energy production can play a crucial role in improv-
ing symptoms in this population. Indeed, mitochondria tar-
geted therapeutic interventions has recently gained attention and
research evaluating its effect has begun in neurodegenerative
disorders, such as PD and Huntington’s disease (Chaturvedi and
Beal, 2013).
One mitochondrial bioenergetics agent studied in previous
literature of PD is creatine, which is involved in energy supply to
the muscle and nerve cells. Briefly, creatine (or phosphocreatine
(PCr) can serve as a temporary ATP source via a reversible
reaction where PCr transfers its phosphate to ADP to form ATP
(Andres et al., 2008). Given that a previous study showed that
creatine exerted a neuroprotective effect on DA neurons of the
SN and depletion of dopamine level in a MPTP induced mouse
model (Matthews et al., 1999), it can be speculated that creatine
supplementation can improve impaired metabolic function in
persons with PD, resulting in protecting DA neurons requiring
high energy for survival (as previously mentioned). Furthermore,
a growing body of literature shows promising benefits of creatine
in improving various parkinsonian symptoms, such as muscle
endurance (Hass et al., 2007), progression of overall UPDRS
score (Ninds Net-Pd Investigators, 2006), and individuals’ mood
(Bender et al., 2006).
In addition, PD has been shown to result in increased
IGF-1 levels, indicative of insulin resistance (see Bassil et al.
(2014) for a review). Data from a small cross-sectional sample
found elevated IGF-1 levels to be correlated with PD symp-
tom severity as measured through Hoehn-Yahr (Numao et al.,
2014). Hence, another alternative therapy would be the use
of medications that improve insulin sensitivity, such as met-
formin, which has now been shown to have a neuroprotec-
tive effect on the MPTP mouse model of PD (Patil et al.,
2014). IGF-1 levels can be lowered and insulin sensitivity
increased through treatment with the growth hormone recep-
tor antagonist, pegvisomant (see van der Lely and Kopchick
(2006) for a review). Further research in this area is needed,
in conjunction with measures of nigrostriatal dopamine neu-
ron loss in order to test the hypotheses beyond that of motor
symptoms.
CONCLUDING REMARKS
Unfortunately, there is currently no cure for PD; thus currently-
available treatment options only focus on alleviating and delaying
motor symptoms associated with PD. Although much progress
has been made to develop and evaluate various treatment options
for this population, including but not limited to DA medications,
deep brain stimulation, and physical activity-based interventions
(resistance training, treadmill training, Tai Chi, etc.), the opti-
mal intervention for this pathological population has to be yet
explored. Instead, there is even contradictory evidence in a recent
mice model study suggesting that exercise does not slow down
progression of symptoms, but even accelerate their progression
or onset of disease in neurological disorders. Specifically, mice
with HD in pre-symptomatic stage completing voluntary wheel
had an earlier onset of HD symptoms and reduced striatal volume
and motor impairments when compared to non-runners (Potter
et al., 2010). They claimed that exercise could be detrimental
to their vulnerable nervous system; thus providing exercise reg-
imens to patients with neurodegenerative disease should be done
carefully.
Taken together, instead of conventional exercise modalities
with little or no benefits, or even adverse effect to symp-
toms, another potential approach to improve parkinsonian
symptoms could be alleviating mitochondrial dysfunction
and associated bioenergetics deficits. Because of this deci-
sive involvement of mitochondrial dysfunction and its asso-
ciate bioenergetic defects, enhancing normal mitochondrial
function and/or improve energy imbalance may be benefi-
cial to improve debilitating symptoms in PD. Effectively, evi-
dence to date ranging from molecular to behavioral studies
lead us to propose the third hypothesis that improvement
of metabolic function/flexibility could lead to better motor
performance in PD. To test this hypothesis, it is impera-
tive to include measurements/calculations of their metabolic
function and/or energy expenditure and examine the rela-
tionship between the improvement in metabolic function and
the one in motor behavior when evaluating any therapeutic
interventions.
We have presented a new theoretical framework that argues
that underlying neural metabolic deficits are central to the
development of PD motor symptoms. This framework in con-
junction with the testable hypotheses proposed in this paper
will provide a novel viewpoint that can elucidate the connec-
tions between metabolic, neural and motor function in PD.
Ultimately, we hope this theory-and-hypotheses paper will lay
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the foundation for future clinical and therapeutic research to
design a precise diagnosis and effective therapeutic interven-
tions on the basis of the corrective knowledge obtained from
interdisciplinary field of sciences, including molecular biology to
behavioral sciences.
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